scholarly journals Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection

2017 ◽  
Vol 8 (1) ◽  
Author(s):  
Rileen Sinha ◽  
Andrew G. Winer ◽  
Michael Chevinsky ◽  
Christopher Jakubowski ◽  
Ying-Bei Chen ◽  
...  
2018 ◽  
Vol 18 (8) ◽  
pp. 1072-1081
Author(s):  
Angel J. Ruiz-Moreno ◽  
Patricia Torres-Barrera ◽  
Mireya Velázquez-Paniagua ◽  
Alexander Dömling ◽  
Marco A. Velasco-Velázquez

Background: Human cancer cell lines are valuable models for anti-cancer drug development. Although all cancer cells share common biological features, each cancer cell line has unique genotypic/ phenotypic characteristics that affect drug response. Thus, the information obtained with a specific cancer cell line cannot be easily extrapolated to other cancer cells. Consequently, cell line selection during experimental design is critical for providing proper and clinically relevant structure-activity analysis. Methods: Herein, we critically review the use of cancer cell lines as tools for activity analysis by comparing two different scenarios: i) the use of multiple cancer cell lines, with the NCI-60 Program as the most representative example; and, ii) the selection of a single cell line with specific biological characteristics that match the rationale of compound design. Results: Considering that most laboratories evaluate the activity of new compounds using few cell lines, we provide a systematic strategy for selection based on the expression levels and genetic status of the target and the effectiveness of target inhibition or silencing. We exemplify the use of public databases for data retrieval and analysis as well as the critical comparison of such information with published results. Conclusion: This approach refines cell line selection, avoiding the perpetuation of published poor selection and enhancing the relevance of the results.


Phytomedicine ◽  
2017 ◽  
Vol 27 ◽  
pp. 1-7 ◽  
Author(s):  
Eva Juengel ◽  
Stephanie Euler ◽  
Sebastian Maxeiner ◽  
Jochen Rutz ◽  
Saira Justin ◽  
...  

2009 ◽  
Vol 181 (4S) ◽  
pp. 112-112
Author(s):  
Joseph Ischia ◽  
Damien M Bolton ◽  
Liesl Ischia ◽  
Oneel Patel ◽  
Rachele Lockie ◽  
...  

Urology ◽  
1999 ◽  
Vol 53 (1) ◽  
pp. 218-222 ◽  
Author(s):  
Mitsuru Noguchi ◽  
Koichiro Nomata ◽  
Jun-ichi Watanabe ◽  
Hidesuke Sato ◽  
Hiroshi Kanetake ◽  
...  

Oncotarget ◽  
2015 ◽  
Vol 6 (21) ◽  
pp. 18418-18428 ◽  
Author(s):  
Paul D. Hanavan ◽  
Chad R. Borges ◽  
Benjamin A. Katchman ◽  
Douglas O. Faigel ◽  
Thai H. Ho ◽  
...  

2020 ◽  
Vol 11 (3) ◽  
pp. 491-496
Author(s):  
Mujahid B Khan ◽  
Ninad Sathe ◽  
Bharat Rathi

The medicines prepared by using exudates of Commiphora mukul (Stocks) Hook. are described in Ayurveda under Guggula Kalpana which are among such valuable dosage forms. According to retrospective literary review, the combination of Kukkutnaki (Aspidium cicutarium Sw.) and purified Guggula(Commiphora mukul (Stocks) Hook.) was first mentioned in the book Chikitsa pradeep named as Kukkutnaki Guggula. Since last 3 decades, it was documented as an herbal drug which is used for cysts, goiter, tumors, tonsillitis, abscess, mansvaha strotas ailments, which are burning issues worldwide. Due to its observed clinical efficacy in Arbuda (~Cancer), the current in-vitro anticancer study was conducted with an aim to check its anticancer effect on human hepatoma cell line-HEPG2 of Liver; PC-3 and DU145 cancer cell lines of Prostate; Ovcar-3, A2780, SK-OV-3, PA-1 cancer cell lines of Ovary and ACHN renal cancer cell line of Kidney. The current in vitro study was conducted at ACTREC, Kharghar, Navi Mumbai. The selected cancer cell lines were procured from ATCC, USA and NCCS Pune. The Sulforhodamine B (SRB) Assay protocol was followed to observe the activity of the study drug. The positive control was Adriamycin in the study. The growth curve graphs were plotted and LC50, GI50, TGI values were calculated. Kukkutnakhi Guggula was found safe for oral administration, non- toxic at cellular level (LC50 values were > 160) and have moderate activity on HEPG2, Ovcar-3, DU145, ACHN cancer cell lines and had shown negligible activity on A2780, SK-OV-3, PA-1 and PC-3 cell lines. This work provides scope to study its effect on targeted cancers, specific in vivo scientific studies and human clinical trials for further researchers.


Sign in / Sign up

Export Citation Format

Share Document